Jasgit C. Sachdev

8.6k citations

126 papers · 3.4k indexed · 1 hit paper · h-index 23

Impact in

Cancer Research top 2%
- MicroRNA in disease regulation
- Cancer-related molecular mechanisms research
Oncology top 2%
- PARP inhibition in cancer therapy
- Cancer Immunotherapy and Biomarkers
- HER2/EGFR in Cancer Research

Papers in ⓘ

Oncology 69
- Cancer Treatment and Pharmacology 21
- HER2/EGFR in Cancer Research 15
- Cancer Immunotherapy and Biomarkers 11
- PARP inhibition in cancer therapy 11
- Lung Cancer Research Studies 11
Cancer Research 25

Co-authors: Mitesh J. Borad (6 shared papers)Jay Stoudemire (6 shared papers)David S. Hong (7 shared papers)Stephen M. Smith (5 shared papers)Sinil Kim (5 shared papers)Andrew Brenner (5 shared papers)Andreas G. Bader (5 shared papers)Yoon‐Koo Kang (3 shared papers)
Journals: Journal of Clinical Oncology (43 papers)Cancer Research (17 papers)Clinical Cancer Research (9 papers)Annals of Oncology (8 papers)European Journal of Cancer (6 papers)
Partner nations: United States United Kingdom Spain

In The Last Decade

Jasgit C. Sachdev

124 papers receiving 3.4k citations

Hit Papers

align trajectories log scale

Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors 2016 · 682 citations

Peers

Countries citing papers authored by Jasgit C. Sachdev

Since Specialization

Citations

This map shows the geographic impact of Jasgit C. Sachdev's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jasgit C. Sachdev with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jasgit C. Sachdev more than expected).

Fields of papers citing papers by Jasgit C. Sachdev

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jasgit C. Sachdev. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jasgit C. Sachdev. The network helps show where Jasgit C. Sachdev may publish in the future.

Co-authors

The 25 scholars most cited alongside Jasgit C. Sachdev, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Jasgit C. Sachdev Line = papers co-authored together Jasgit C. Sachdev links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 126 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors Investigational New Drugs ·Muhammad S. Beg, Andrew Brenner, Jasgit C. Sachdev, Mitesh J. Borad, Yoon‐Koo Kang, Jay Stoudemire, Stephen M. Smith, Andreas G. Bader, Sinil Kim, David S. Hong Hit paper breakdown →	2016	682
2	Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers Cancer Discovery ·Johann S. de Bono, Ramesh K. Ramanathan, Lida A. Mina, Rashmi Chugh, John A. Glaspy, Saeed Rafii, Stan B. Kaye, Jasgit C. Sachdev, John V. Heymach, David C. Smith, Joshua W. Henshaw, Ashleigh Herriott, Miranda Patterson, Nicola J. Curtin, Lauren A. Byers, Zev A. Wainberg	2017	314
3	Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer Clinical Cancer Research ·Hope S. Rugo, Jean‐Pierre Delord, Seock‐Ah Im, Patrick A. Ott, Sarina A. Piha‐Paul, Philippe L. Bédard, Jasgit C. Sachdev, Christophe Le Tourneau, Emilie M.J. van Brummelen, Andréa Varga, Roberto Salgado, Sherene Loi, Sanatan Saraf, Dina Pietrangelo, Vassiliki Karantza, Antoinette R. Tan	2018	264
4	Phase I Study of PSMA-Targeted Docetaxel-Containing Nanoparticle BIND-014 in Patients with Advanced Solid Tumors Clinical Cancer Research ·Daniel D. Von Hoff, Monica Mita, Ramesh K. Ramanathan, Glen J. Weiss, Alain C. Mita, Patricia LoRusso, Howard A. Burris, Lowell L. Hart, Susan C. Low, Donald M. Parsons, Stephen E. Zale, Jason M. Summa, Hagop Youssoufian, Jasgit C. Sachdev	2016	215
5	AKT in cancer: new molecular insights and advances in drug development British Journal of Clinical Pharmacology ·Prabhjot S. Mundi, Jasgit C. Sachdev, Carolyn K. McCourt, Kevin Kalinsky	2016	213
6	Correlation between Ferumoxytol Uptake in Tumor Lesions by MRI and Response to Nanoliposomal Irinotecan in Patients with Advanced Solid Tumors: A Pilot Study Clinical Cancer Research ·Ramesh K. Ramanathan, Ronald L. Korn, Natarajan Raghunand, Jasgit C. Sachdev, Ronald G. Newbold, Gayle Jameson, Gerald J. Fetterly, Joshua Prey, Stephan G. Klinz, Jaeyeon Kim, Jason E. Cain, Bart S. Hendriks, Daryl C. Drummond, Eliel Bayever, Jonathan B. Fitzgerald	2017	134
7	First-in-Human Study of Mivebresib (ABBV-075), an Oral Pan-Inhibitor of Bromodomain and Extra Terminal Proteins, in Patients with Relapsed/Refractory Solid Tumors Clinical Cancer Research ·Sarina A. Piha‐Paul, Jasgit C. Sachdev, Minal Barve, Patricia LoRusso, Russell Z. Szmulewitz, Sapna P. Patel, Primo N. Lara, Xiaotian Chen, Beibei Hu, Kevin J. Freise, Dimple Modi, Anjla Sood, Jessica E. Hutti, Johannes Wolff, Bert H. O’Neil	2019	116
8	TOPACIO/Keynote-162 (NCT02657889): A phase 1/2 study of niraparib + pembrolizumab in patients (pts) with advanced triple-negative breast cancer or recurrent ovarian cancer (ROC)—Results from ROC cohort. Journal of Clinical Oncology ·Panagiotis A. Konstantinopoulos, Steven Waggoner, Gregory A. Vidal, Monica Mita, Gini F. Fleming, Robert W. Holloway, Linda Van Le, Jasgit C. Sachdev, Eloise Chapman‐Davis, Gerardo Colón‐Otero, Richard T. Penson, Ursula A. Matulonis, Young B. Kim, Kathleen N. Moore, Elizabeth M. Swisher, Bruce J. Dezube, Jing Y. Wang, Nathan Buerstatte, Sujata Arora, Pamela N. Münster	2018	108
9	Abstract S5-07: Preliminary efficacy and safety of pembrolizumab (MK-3475) in patients with PD-L1–positive, estrogen receptor-positive (ER+)/HER2-negative advanced breast cancer enrolled in KEYNOTE-028 Cancer Research ·HS Rugo, J.P. Delord, S-A. Im, P.A. Ott, SA Piha-Paul, PL Bedard, Jasgit C. Sachdev, Christophe Le Tourneau, Emilie M.J. van Brummelen, Andréa Varga, Sanatan Saraf, Dina Pietrangelo, Vassiliki Karantza, Antoinette R. Tan	2016	77
10	A Phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours British Journal of Cancer ·Kyriakos P. Papadopoulos, Bassell F. El-Rayes, Anthony W. Tolcher, Amita Patnaik, Drew Rasco, R. Donald Harvey, Patricia LoRusso, Jasgit C. Sachdev, Giovanni Abbadessa, Ronald E. Savage, Traci M. Tanaka Hall, Brian Schwartz, Y. Wang, Julia Kazakin, Walid L. Shaib	2017	76
11	First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody–Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid Tumors Clinical Cancer Research ·Michael L. Maitland, Jasgit C. Sachdev, Manish Sharma, Víctor Moreno, Valentina Boni, Shivaani Kummar, Erica Stringer-Reasor, Nehal J. Lakhani, Allison Moreau, Dawei Xuan, Ray Li, Eric L. Powell, Amy Jackson-Fisher, Michelle Bowers, Shilpa Alekar, Xiaohua Xin, Anthony W. Tolcher, Emiliano Calvo	2021	63
12	First-in-human trial of novel oral PARP inhibitor BMN 673 in patients with solid tumors. Journal of Clinical Oncology ·Johann S. de Bono, Lida A. Mina, Michael Gonzalez, Nicola J. Curtin, Evelyn Wang, Joshua W. Henshaw, Manpreet Chadha, Jasgit C. Sachdev, Daniela Matei, Gayle Jameson, Michael Ong, Bristi Basu, Zev A. Wainberg, Lauren A. Byers, Rashmi Chugh, Andrew Dorr, Stanley B. Kaye, Ramesh K. Ramanathan	2013	61
13	Effect of Capivasertib in Patients With an AKT1 E17K-Mutated Tumor JAMA Oncology ·Kevin Kalinsky, Fangxin Hong, Carolyn K. McCourt, Jasgit C. Sachdev, Edith P. Mitchell, James A. Zwiebel, L. Austin Doyle, Lisa M. McShane, Shuli Li, Robert J. Gray, Larry Rubinstein, David R. Patton, P. Mickey Williams, Stanley R. Hamilton, Barbara A. Conley, Peter J. O’Dwyer, Lyndsay N. Harris, Carlos L. Arteaga, Alice P. Chen, Keith T. Flaherty	2020	58
14	A pilot study utilizing multi-omic molecular profiling to find potential targets and select individualized treatments for patients with previously treated metastatic breast cancer Breast Cancer Research and Treatment ·Gayle Jameson, Emanuel F. Petricoin, Jasgit C. Sachdev, Lance A. Liotta, David Loesch, Stephen P. Anthony, Manpreet Chadha, Julia Wulfkuhle, Rosa I. Gallagher, Kimberley A. Reeder, Mariaelena Pierobon, Monica Fulk, Nina Cantafio, Bryant Dunetz, William Mikrut, Daniel D. Von Hoff, Nicholas J. Robert	2014	57
15	Safety, Pharmacokinetics, and Pharmacodynamics of a Humanized Anti-Semaphorin 4D Antibody, in a First-In-Human Study of Patients with Advanced Solid Tumors Clinical Cancer Research ·Amita Patnaik, Glen J. Weiss, John E. Leonard, Drew Rasco, Jasgit C. Sachdev, Terrence L. Fisher, Laurie A. Winter, Christine Reilly, Robert B. Parker, Danielle Mutz, Lisa Blaydorn, Anthony W. Tolcher, Maurice Zauderer, Ramesh K. Ramanathan	2015	50
16	Phase I study of imalumab (BAX69), a fully human recombinant antioxidized macrophage migration inhibitory factor antibody in advanced solid tumours British Journal of Clinical Pharmacology ·Devalingam Mahalingam, Manish R. Patel, Jasgit C. Sachdev, Lowell L. Hart, Niels Halama, Ramesh K. Ramanathan, John Sarantopoulos, Dirk Völkel, Ashraf Youssef, Floris A. de Jong, Apostolia M. Tsimberidou	2020	49
17	Phase I study of liposomal irinotecan in patients with metastatic breast cancer: findings from the expansion phase Breast Cancer Research and Treatment ·Jasgit C. Sachdev, Pamela N. Münster, Donald W. Northfelt, Hyo S. Han, X. Cynthia, Fiona Maxwell, Tiffany Wang, Bruce Belanger, Bin Zhang, Yan Moore, Arunthathi Thiagalingam, Carey K. Anders	2020	33
18	Blockade of the HER Family of Receptors in the Treatment of HER2-Positive Metastatic Breast Cancer Clinical Breast Cancer ·Jasgit C. Sachdev, Mohammad Jahanzeb	2011	28
19	Safety and antitumor activity of the PARP inhibitor BMN673 in a phase 1 trial recruiting metastatic small-cell lung cancer (SCLC) and germline BRCA-mutation carrier cancer patients. Journal of Clinical Oncology ·Zev A. Wainberg, Saeed Rafii, Ramesh K. Ramanathan, Lida A. Mina, Lauren A. Byers, Rashmi Chugh, Jonathan W. Goldman, Jasgit C. Sachdev, Daniela Matei, Jennifer J. Wheler, Joshua W. Henshaw, Charlie Zhang, Gilles Gallant, Johann S. de Bono	2014	28
20	MRX34, a liposomal miR-34 mimic, in patients with advanced solid tumors: Final dose-escalation results from a first-in-human phase I trial of microRNA therapy. Journal of Clinical Oncology ·David S. Hong, Yoon‐Koo Kang, Andrew Brenner, Jasgit C. Sachdev, Samuel Ejadi, Mitesh J. Borad, Tae‐You Kim, Ho Yeong Lim, Keunchil Park, Carlos Becerra, Andreas G. Bader, Jay Stoudemire, Stephen M. Smith, Sinil Kim, Muhammad Shaalan Beg	2016	28

About Jasgit C. Sachdev

Jasgit C. Sachdev is a scholar working on Oncology, Cancer Research, Pulmonary and Respiratory Medicine, Reproductive Medicine and Radiology, Nuclear Medicine and Imaging, having authored 126 papers that have together received 3.4k indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (21 papers), Advanced Breast Cancer Therapies (17 papers), HER2/EGFR in Cancer Research (15 papers), Cancer Immunotherapy and Biomarkers (11 papers), PI3K/AKT/mTOR signaling in cancer (11 papers), PARP inhibition in cancer therapy (11 papers), Lung Cancer Research Studies (11 papers) and Lung Cancer Treatments and Mutations (11 papers). The work is most often cited by research in Cancer Research (947 citations), Oncology (1.6k citations), Molecular Biology (1.7k citations), Biomaterials (330 citations) and Immunology (483 citations). Jasgit C. Sachdev has collaborated with scholars based in United States, United Kingdom and Spain. Frequent co-authors include Mitesh J. Borad, Jay Stoudemire, David S. Hong, Stephen M. Smith, Sinil Kim, Andrew Brenner, Andreas G. Bader, Yoon‐Koo Kang, Muhammad S. Beg and Ramesh K. Ramanathan. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research, Clinical Cancer Research, Annals of Oncology and European Journal of Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact